Abstract:Introduction The STAT3 signaling pathway regulates activation of hepatic stellate cells (HSCs) and promotes its fibrogenic behavior. Using a fragment‐based drug design approach, our group has developed HJC0416, a novel orally bioavailable small‐molecule inhibitor of STAT3. HJC0416 was found to induce apoptosis and decreased tumor growth in breast cancer models. In the present study, we studied the antifibrogenic properties of HJC0416 in activated hepatic stellate cells (HSC), which are the major effector cells of liver fibrosis. Methods Human (LX‐2) and rat (HSC‐T6) hepatic stellate cell lines were used. Cell proliferation was measured by Alamar Blue assay. Cellular protein expression levels were determined by Western blotting and immunofluorescence. Cell cycle was assessed by flow cytometry. Yo‐pro‐1 staining was used to measure apoptosis. Results HJC0416 treatment significantly inhibited LX‐2 and HSC‐T6 cell proliferation in a dose‐dependent fashion, and induced apoptosis and S‐phase cell cycle arrest. HSC activation marker α‐smooth muscle actin was also attenuated. HJC0416 suppressed Tyr705‐phosphorylated STAT3 (pSTAT3) and impaired pSTAT3 nuclear translocation and transcriptional activity. STAT3 target genes cyclin D1 and c‐myc were down‐regulated by HJC0416. Static, a well‐known STAT3 inhibitor, confirmed that HSC proliferation was suppressed by STAT3 inhibition. Extracellular matrix (ECM) proteins collagen type I (Coll.I) and fibronectin (FN) are major components of hepatic scar, with TGFβ being the most potent stimulator for ECM production. Our data revealed that endogenous Coll.I and FN expression were suppressed by HJC0416 in a dose‐dependent manner; TGFβ‐stimulated Coll.I and FN production were prevented by pretreatment with HJC0416. Conclusion HJC0416 inhibits HSC activation via the STAT3 signaling pathway. HJC0416 represents a promising anti‐hepatic fibrogenic agent. Support or Funding Information This work was supported by grants P50 CA097007, P30 DA028821, R21 MH098344 (JZ) from the National Institutes of Health, Cancer Prevention Research Institute of Texas award, R. A. Welch Foundation Chemistry and Biology Collaborative Grant (JZ) from the Gulf Coast Consortia, and John Sealy Memorial Endowment Fund and the Center for Addiction Research (JZ) from the University of Texas Medical Branch.

Novel Oridonin Analog CYD0682 Inhibits Hepatic Stellate Cell Activation via the Heat Shock Protein 90-Dependent STAT3 Pathway

Enhanced Effects of Novel Oridonin Analog Cyd0682 for Hepatic Fibrosis

STAT3 Inhibition Suppresses Hepatic Stellate Cell Fibrogenesis: HJC0123, a Potential Therapeutic Agent for Liver Fibrosis.

The Inhibitory Effects of Hjc0416 on Liver Fibrogenesis in Activated Hepatic Stellate Cells

Suppressive Effects of Novel Oridonin Derivative CYD0625 on Activated Hepatic Stellate Cells

Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells

HJC0416, a Small-Molecule Inhibitor of STAT3, Exhibits Anti-Fibrogenic Properties on Activated Hepatic Stellate Cells

Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis.

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

Oligomeric Proanthocyanidin Derived from Grape Seeds Inhibited NF-κB Signaling in Activated HSC: Involvement of JNK/ERK MAPK and PI3K/Akt Pathways

Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation

Pharmacological inhibition of STAT3 pathway ameliorates acute liver injury in vivo via inactivation of inflammatory macrophages and hepatic stellate cells

An RORα agonist, ODH-08, inhibits fibrogenic activation of hepatic stellate cells via suppression of SMAD3

Inhibition of hepatic stellate cell proliferation by heat shock protein 90 inhibitors in vitro

The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis

Oridonin Induces Apoptosis and Cell Cycle Arrest in Activated Hepatic Stellate Cells and Reduces Proliferation and Extracellular Matrix Protein Production

STAT3 Decoy Oligodeoxynucleotides Suppress Liver Inflammation and Fibrosis in Liver Cancer Cells and a DDC-Induced Liver Injury Mouse Model

Cynarin Inhibits PDGF-BB-induced Proliferation and Activation in Hepatic Stellate Cells Through PPARγ

Sa1684 Attenuation of Hepatic Fibrogenesis and Portal Hypertension in the Cirrhotic Rats with Celecoxib and Octreotide

BAY 41-2272 Attenuates CTGF Expression via sGC/cGMP-Independent Pathway in TGFβ1-Activated Hepatic Stellate Cells

A Novel Synthetic Oleanolic Acid Derivative (Cpu-Ii2) Attenuates Liver Fibrosis in Mice Through Regulating the Function of Hepatic Stellate Cells